<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335321</url>
  </required_header>
  <id_info>
    <org_study_id>2010/11450-9</org_study_id>
    <nct_id>NCT01335321</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation</brief_title>
  <official_title>Prospective And Randomized Study Evaluating Tthe Effect Of The Association Of Triamcinolone To The Viscosupplementation Of The Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the investigators can achieve better early
      outcomes adding triamcinolone to the viscosupplementation procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      So far there is no convincing evidence that any treatment can be really effective in slowing
      or preventing the development of OA. The viscosupplementation by intraarticular injection of
      hyaluronate-derived products has gained popularity as a treatment modality of gonarthrosis.
      Today there are various papers on the treatment of gonarthrosis by intraarticular injection.
      Several methods have shown good results. There isn't, however, a consensus on the best
      method. The investigators know that in the treatment of osteoarthritis, with the
      viscosupplementation Hylan is superior in the long term, than the infiltration with
      cortisone. The good short term results achieved by infiltration of cortisone make us think
      about the combination of these drugs. The investigators will be assessing 104 patients with
      osteoarthritis of the knee, divided into two groups. Patients in group 1 will be subjected to
      infiltration procedure 6ml of Hylan. Patients in Group 2 will undergo the procedure of
      infiltration with 6ml of Hylan and 1ml (20mg) of hexacetonide Triamcinolone. The researcher
      will apply the informed consent term, the pain visual analog scale (VAS), WOMAC and Lequesne
      questionnaires. The questionnaires will be answered before infiltration (week zero), one week
      after the puncture (week 1), four weeks after (week 4) and 12 weeks after (week 12) and 24
      weeks after (week 24).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Results in WOMAC, Lequesne and VAS scores</measure>
    <time_frame>4 weeks</time_frame>
    <description>The outcome will be measured with the WOMAC and LEQUESNE scores, both about quality of life and knee function. The subjects will also use the VAS (VISUAL ANALOGIC SCALE) of pain. The results will be compared between the two groups within 1 week and 4 weeks after the viscosupplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Results in WOMAC, Lequesne and VAS scores after 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>The investigators are also going to compare the results after 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hylan GF-20 alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive a knee infiltration with 6ml of Hylan GF-20 only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylan GF-20 alone</intervention_name>
    <description>A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)</description>
    <arm_group_label>Hylan GF-20 alone</arm_group_label>
    <other_name>Synvisc One</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)</description>
    <arm_group_label>Triamcinolone</arm_group_label>
    <other_name>Synvisc One and Triancil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 45 and 80 years

          -  Osteoarthritis Diagnosis with radiographic evidence

          -  absence of previous intraarticular knee fracture

          -  absence of allergy to Synvisc or Triancil

        Exclusion Criteria:

          -  Development of Pioarthritis

          -  Failure to attend to the consultations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olavo Pires de Camargo, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Faculdade de Medicina da Universidade de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Ortopedia e Traumatologia do Hospital das Clínicas da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R. The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheumatol Int. 2006 Feb;26(4):314-9. Epub 2005 Feb 10.</citation>
    <PMID>15703953</PMID>
  </reference>
  <reference>
    <citation>Brander VA, Stadler TS. Functional improvement with hylan G-F 20 in patients with knee osteoarthritis. Phys Sportsmed. 2009 Oct;37(3):38-48. doi: 10.3810/psm.2009.10.1728. Review.</citation>
    <PMID>20048527</PMID>
  </reference>
  <reference>
    <citation>Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee -- a prospective randomized clinical trial. Knee. 2008 Aug;15(4):318-24. doi: 10.1016/j.knee.2008.02.012. Epub 2008 Apr 21.</citation>
    <PMID>18430574</PMID>
  </reference>
  <reference>
    <citation>Goorman SD, Watanabe TK, Miller EH, Perry C. Functional outcome in knee osteoarthritis after treatment with hylan G-F 20: a prospective study. Arch Phys Med Rehabil. 2000 Apr;81(4):479-83.</citation>
    <PMID>10768539</PMID>
  </reference>
  <reference>
    <citation>Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005 Aug;21(8):1261-9.</citation>
    <PMID>16083536</PMID>
  </reference>
  <reference>
    <citation>Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009 Dec 15;61(12):1704-11. doi: 10.1002/art.24925. Review.</citation>
    <PMID>19950318</PMID>
  </reference>
  <reference>
    <citation>Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321. Review.</citation>
    <PMID>16625635</PMID>
  </reference>
  <reference>
    <citation>Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, Bailleul F, Pavelka K. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010 Jan;69(1):113-9. doi: 10.1136/ard.2008.094623.</citation>
    <PMID>19304567</PMID>
  </reference>
  <reference>
    <citation>Conrozier T, Jerosch J, Beks P, Kemper F, Euller-Ziegler L, Bailleul F, Chevalier X. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg. 2009 Mar;129(3):417-23. doi: 10.1007/s00402-008-0601-2. Epub 2008 Mar 26.</citation>
    <PMID>18365224</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Marcia Uchoa Rezende</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>viscosupplementation</keyword>
  <keyword>intra-articular injection</keyword>
  <keyword>hyaluronic acid</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

